Callodine Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Callodine Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-115,000	Closed	-$6.67M	–	39
2023 Q3	$6.67M	Sell	115,000 -5,000	-4%	-$306K	1.86%	26
2023 Q2	$7.67M	Buy	120,000 +35,000	+41%	+$2.35M	2.2%	16
2023 Q1	$5.89M	Buy	85,000 +5,000	+6%	+$353K	1.74%	21
2022 Q4	$5.76M	Sell	80,000 -85,000	-52%	-$6.41M	1.71%	21
2022 Q3	$11.7M	Buy	165,000 +92,500	+128%	+$6.71M	3.65%	11
2022 Q2	$5.58M	Sell	72,500 -182,500	-72%	-$13.9M	1.65%	25
2022 Q1	$18.6M	Sell	255,000 -15,000	-6%	-$1.01M	5.98%	1
2021 Q4	$16.8M	Sell	270,000 -30,000	-10%	-$1.76M	6.53%	1
2021 Q3	$17.8M	Buy	300,000 +22,500	+8%	+$1.48M	6.69%	1
2021 Q2	$18.5M	Buy	277,500 +15,000	+6%	+$978K	7%	2
2021 Q1	$16.6M	Buy	262,500 +62,500	+31%	+$3.89M	7.19%	2
2020 Q4	$12.4M	Buy	200,000 +30,625	+18%	+$1.88M	6%	3
2020 Q3	$10.2M	Sell	169,375 -20,625	-11%	-$1.24M	5.44%	5
2020 Q2	$11.2M	Sell	190,000 -205,000	-52%	-$12.3M	5.48%	7
2020 Q1	$22M	Buy	395,000 +85,000	+27%	+$5.2M	8.96%	3
2019 Q4	$19.9M	Buy	310,000 +40,000	+15%	+$2.29M	7.88%	5
2019 Q3	$13.7M	Buy	270,000 +210,000	+350%	+$9.87M	5.48%	6
2019 Q2	$2.72M	Buy	+60,000	New	+$2.79M	1.19%	23

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Callodine Capital Management's BMY Position: Q4 2023 in Review

Callodine Capital Management sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 115,000 shares — an estimated $6.67M sold.

Callodine Capital Management first reported a position in BMY in Q2 2019 and held it in 18 quarters. The position peaked at $22M in Q1 2020. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Callodine Capital Management reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Callodine Capital Management sold 115,000 Bristol-Myers Squibb shares in Q4 2023, an estimated $6.67M.
Callodine Capital Management first reported a position in Bristol-Myers Squibb in Q2 2019 and held it in 18 quarters.
Callodine Capital Management's Bristol-Myers Squibb position peaked at $22M in Q1 2020.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Callodine Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.